Sargramostim vs placebo:• Increased monocyte HLA-DR expression to a level no different from healthy controls (p=0.27)• Positive correlation between HLA-DR expression and infection clearance (r=0.41; p=0.02)• Reversed the suppression and upregulated number of CD11b functional markers on circulating neutrophils and monocytes (p<0.01). The gene discussed is ITGAM; the disease is infection.